IDEAYA Biosciences Inc IDYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
-
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
-
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
-
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
-
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
Trading Information
- Previous Close Price
- $37.28
- Day Range
- $35.92–37.42
- 52-Week Range
- $21.33–40.58
- Bid/Ask
- $34.50 / $40.63
- Shares Outstanding
- 96.27M
- Market Cap
- $3.56B
- Volume/Avg
- 677,503 / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 15.93
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- < 0.01%
Company Profile
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 145
- Website
- https://www.ideayabio.com
Valuation
|
Metric
|
IDYA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.80 |
Price/Sales | 15.93 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IDYA
|
|---|---|
Quick Ratio | 10.45 |
Current Ratio | 10.74 |
Interest Coverage | — |
Quick Ratio
IDYA
Profitability
|
Metric
|
IDYA
|
|---|---|
Return on Assets (Normalized) | −8.20% |
Return on Equity (Normalized) | −8.90% |
Return on Invested Capital (Normalized) | −12.86% |
Return on Assets
IDYA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|t^&>V<C | LOCK|##>ML | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<mTW@D | LOCK|LC$V | $70B | |||
| argenx SE ADR
ARGX
| LOCK|ZqXt<& | LOCK|%#$ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@@hJgq | LOCK|kFN& | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|R>QDfh | LOCK|wB | $36B | |||
| Moderna Inc
MRNA
| LOCK|$#^$@>% | LOCK|?b | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|B>@SS?<l | LOCK|wDmqY | $25B | |||
| Incyte Corp
INCY
| LOCK|?Wwzd#r | LOCK|&% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|DN@wVl | LOCK|?$ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|yX@>>v& | LOCK|&% | $17B |
United States